Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
European physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol. The study evaluates if selecting the starting dose based on baseline and target LDL-C cholesterol would provide better results (ie proportion of subjects resching target)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Atorvastatin (Lipitor) | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of subjects achieving a LDL-C target of < 100 mg/dL (2.6 mmol/L) after 12 weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of subjects achieving: | ||
| LDL-C target <100 mg/dL (<2.6 mmol/L) after 6 weeks of treatment. | ||
| Total cholesterol (TC)/HDL-C ratio target (<4.0) after 6 and 12 weeks of treatment. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Ioannina | Greece | ||||
| Pfizer Investigational Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 17626713 | Derived | Farsang C, Athyros V, Gaw A; ACTFAST-2 investigators and Steering Committee members. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study. Curr Med Res Opin. 2007 Aug;23(8):1945-56. doi: 10.1185/030079907X223242. |
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Either the LDL-C <100mg/dL (<2.6 mmol/L) or TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment. |
| Both the LDL-C <100mg/dL (<2.6 mmol/L) and TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment. |
| LDL-C <100mg/dL (<2.6 mmol/L) or TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment by LDL-C strata. |
| LDL-C target (<100 mg/dL) by primary inclusion diagnosis (CHD, CHD-equivalent, diabetes or 10-year CHD risk-equivalent >20%). |
| The mean percent change in LDL-C, high density lipoprotein cholesterol (HDL-C),TC/HDL-C ratio, non HDL-C (in subjects with triglycerides [TG] ≥200 mg/dL or 2.3 mmol/L), TC and TG from baseline to 6 and 12 weeks of treatment. Change from baseline in apol |
| Kallithea, Athens |
| Greece |
| Pfizer Investigational Site | Pireaus | Greece |
| Pfizer Investigational Site | Thessaloniki | Greece |
| Pfizer Investigational Site | Budapest | Hungary |
| Pfizer Investigational Site | Gyula | Hungary |
| Pfizer Investigational Site | Kecskemét | Hungary |
| Pfizer Investigational Site | Nyíregyháza | Hungary |
| Pfizer Investigational Site | Szekszárd | Hungary |
| Pfizer Investigational Site | Tullamore | CO. Offlay | Ireland |
| Pfizer Investigational Site | Tallaght | Dublin | Ireland |
| Pfizer Investigational Site | Gorey | Wexford | Ireland |
| Pfizer Investigational Site | Cork | Ireland |
| Pfizer Investigational Site | Dublin | Ireland |
| Pfizer Investigational Site | Galway | Ireland |
| Pfizer Investigational Site | Częstochowa | Poland |
| Pfizer Investigational Site | Poznan | Poland |
| Pfizer Investigational Site | Warsaw | Poland |
| Pfizer Investigational Site | Wroclaw | Poland |
| Pfizer Investigational Site | Zabrze | Poland |
| Pfizer Investigational Site | Aveiro | Portugal |
| Pfizer Investigational Site | Lisbon | Portugal |
| Pfizer Investigational Site | Porto | Portugal |
| Pfizer Investigational Site | Vila Franca de Xira | Portugal |
| Pfizer Investigational Site | Moscow | Russia |
| Pfizer Investigational Site | Bratislava | Slovakia |
| Pfizer Investigational Site | Košice | Slovakia |
| Pfizer Investigational Site | Bern | Switzerland |
| Pfizer Investigational Site | Geneva | Switzerland |
| Pfizer Investigational Site | Mendrisio | Switzerland |
| Pfizer Investigational Site | Zurich | Switzerland |
| Pfizer Investigational Site |
| ID | Term |
|---|---|
| D003324 | Coronary Artery Disease |
| D003924 | Diabetes Mellitus, Type 2 |
| D020521 | Stroke |
| D050171 | Dyslipidemias |
| D016491 | Peripheral Vascular Diseases |
| ID | Term |
|---|---|
| D003327 | Coronary Disease |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D052439 | Lipid Metabolism Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069059 | Atorvastatin |
| ID | Term |
|---|---|
| D011758 | Pyrroles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006538 | Heptanoic Acids |
| D005227 | Fatty Acids |
| D008055 | Lipids |
Not provided
Not provided